Table 3.
Univariate analysis to assess the relationship between miR-224-5p and miR-489 expression level deregulation, and clinic-pathological and molecular features.
| Variables | miR-224-5p | miR-489 | |||
|---|---|---|---|---|---|
| OR (95% CI) | p Value | OR (95% CI) | p Value | ||
| Localization | Right | 1.2 (0.2–6.6) | 0.85 | - | - |
| Left | 0.4 (0.1–2.4) | 0.34 | 0.4 (0.1–2.3) | 0.30 | |
| Rectum | - | - | 5.4 (0.9–34.2) | 0.07 | |
| Tumor stage | I | - | - | 0.5 (0.1–5.0) | 0.57 |
| II | 0.8 (0.1–8.4) | 0.86 | - | - | |
| III | 1.8 (0.3–11.0) | 0.53 | 1.3 (0.2–7.1) | 0.80 | |
| IV | 0.1 (0.0–0.7) | 0.02 | 4 (0.6–29.3) | 0.17 | |
| Histologic grade | G1 | - | - | 7.2 (0.4–134.2) | 0.19 |
| G2 | 1.2 (0.2–7.4) | 0.86 | 0.9 (0.1–5.3) | 0.86 | |
| G3 | 0.6 (0.1–4.1) | 0.64 | 0.5 (0.1–5.2) | 0.59 | |
| Tumor infiltrating lymphocytes | 0.7 (0.1–4.5) | 0.67 | - | - | |
| KRAS mutational status | 3.4 (0.4–32.2) | 0.28 | 4.2 (0.7–26.0) | 0.13 | |
OR: odds ratio; CI: confidence interval. The p values are bold where they are less than or equal to the significance level of 0.05.